Back to Search
Start Over
Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
- Source :
- Experimental Hematology & Oncology, Vol 10, Iss 1, Pp 1-4 (2021)
- Publication Year :
- 2021
- Publisher :
- BMC, 2021.
-
Abstract
- Abstract Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax.
Details
- Language :
- English
- ISSN :
- 21623619
- Volume :
- 10
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Experimental Hematology & Oncology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.7b18812b0b844ab9876c76ff71de96d7
- Document Type :
- article
- Full Text :
- https://doi.org/10.1186/s40164-020-00186-y